ArticleEuropean radiology2020
Hepatocellular adenomas: is there additional value in using Gd-EOB-enhanced MRI for subtype differentiation?
Article in European radiology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 18 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Exploring radiological characteristics in beta-catenin-mutated hepatocellular adenoma: a systematic review and meta-analysis.Abdominal radiology (New York) · 2026Pooled it
- Hepatic Adenoma Subtypes on Hepatobiliary Phase of Gadoxetic Acid-Enhanced MRI: Systematic Review and Meta-Analysis.AJR. American journal of roentgenology · 2023Pooled it
- Hyperintense liver lesions on hepatobiliary phase of gadoxetic acid-enhanced magnetic resonance imaging: clinical insights and significance.Abdominal radiology (New York) · 2026Review
- Gd-EOB-DTPA-enhanced hepatobiliary phase MRI characteristics of inflammatory hepatic adenoma.BMC medical imaging · 2025Article
- Modified LR-5 criteria based on gadoxetic acid can improve the sensitivity in the diagnosis of hepatocellular carcinoma.World journal of radiology · 2025Article
- Lesions hyper- to isointense to surrounding liver in the hepatobiliary phase of gadoxetic acid-enhanced MRI.European radiology · 2024Article
- Hepatocellular adenoma update: diagnosis, molecular classification, and clinical course.The British journal of radiology · 2024Review
- WFUMB Review Paper. Incidental Findings in Otherwise Healthy Subjects, How to Manage: Liver.Cancers · 2024Review
- Intrahepatic Mass-Forming Cholangiocarcinoma: Is There Additional Prognostic Value in Using Gd-EOB Enhanced MRI?Cancers · 2024Article
- Key CT and MRI findings of drug-associated hepatobiliary and pancreatic disorders.Japanese journal of radiology · 2024Review
- [Analysis of MRI features of hepatocyte nuclear factor 1α-inactivated hepatocellular adenoma].Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology · 2023Article
- A rare case of MRI of myxoid hepatocellular adenoma with gadoxetic acid uptake.BJR case reports · 2023Article
- Imaging features of β-catenin-activated hepatocellular adenoma with weak β-catenin activation: A rare case report.Acta radiologica open · 2022Article
- Differentiation of hepatocellular adenoma by subtype and hepatocellular carcinoma in non-cirrhotic liver by fractal analysis of perfusion MRI.Insights into imaging · 2022Article
- Scoping review of clinical practice guidelines on the management of benign liver tumours.BMJ open gastroenterology · 2021Article
- A case study of glycogen storage disease type Ia presenting with multiple hepatocellular adenomas: an analysis by gadolinium ethoxybenzyl-diethylenetriamine-pentaacetic acid magnetic resonance imaging.Quantitative imaging in medicine and surgery · 2021Article
- HBP-enhancing hepatocellular adenomas and how to discriminate them from FNH in Gd-EOB MRI.BMC medical imaging · 2021Article
- Spectrum of liver lesions hyperintense on hepatobiliary phase: an approach by clinical setting.Insights into imaging · 2021Review
Corrections and comments
- Erratum issued
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeTo differentiate subtypes of hepatocellular adenoma (HCA) based on enhancement characteristics in gadoxetic acid (Gd-EOB) magnetic resonance imaging (MRI). MATERIALS AND
methodsForty-eight patients with 79 histopathologically proven HCAs who underwent Gd-EOB-enhanced MRI were enrolled (standard of reference: surgical resection). Two blinded radiologists performed quantitative measurements (lesion-to-liver enhancement) and evaluated qualitative imaging features. Inter-reader variability was tested. Advanced texture analysis was used to evaluate lesion heterogeneity three-dimensionally.
resultsOverall, there were 19 (24%) hepatocyte nuclear factor (HNF)-1a-mutated (HHCAs), 37 (47%) inflammatory (IHCAs), 5 (6.5%) b-catenin-activated (bHCA), and 18 (22.5%) unclassified (UHCAs) adenomas. In the hepatobiliary phase (HBP), 49.5% (39/79) of all adenomas were rated as hypointense and 50.5% (40/79) as significantly enhancing (defined as > 25% intralesional GD-EOB uptake). 82.5% (33/40) of significantly enhancing adenomas were IHCAs, while only 4% (1/40) were in the HHCA subgroup (p < 0.001). When Gd-EOB uptake behavior was considered in conjunction with established MRI features (binary regression model), the area under the curve (AUC) increased from 0.785 to 0.953 for differentiation of IHCA (atoll sign + hyperintensity), from 0.859 to 0.903 for bHCA (scar + hyperintensity), and from 0.899 to 0.957 for HHCA (steatosis + hypointensity). Three-dimensional region of interest (3D ROI) analysis showed significantly increased voxel heterogeneity for IHCAs (p = 0.038).
conclusionGd-EOB MRI is of added value for subtype differentiation of HCAs and reliably identifies the typical heterogeneous HBP uptake of IHCAs. Diagnostic accuracy can be improved significantly by the combined analysis of established morphologic MR appearances and intralesional Gd-EOB uptake. KEY POINTS: •Gd-EOB-enhanced MRI is of added value for subtype differentiation of HCA. •IHCA and HHCA can be identified reliably based on their typical Gd-EOB uptake patterns, and accuracy increases significantly when additionally taking established MR appearances into account. •The small numbers of bHCAs and UHCAs remain the source of diagnostic uncertainty.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.